Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-06-2009 | Retinal Disorders

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

Authors: J. Fernando Arevalo, Juan G. Sanchez, Jans Fromow-Guerra, Lihteh Wu, Maria H. Berrocal, Michel E. Farah, Jose Cardillo, Francisco J. Rodríguez, for the Pan-American Collaborative Retina Study Group (PACORES)

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2009

Abstract

Background

To report the 12-month anatomic and ETDRS best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin®) (1.25 mg or 2.5 mg) in patients with diffuse diabetic macular edema (DDME). In addition, a comparison of the two different doses of intravitreal bevacizumab (IVB) utilized was made.

Methods

We reviewed the clinical records of 82 consecutive patients (101 eyes) with DDME in this interventional retrospective multicenter study. All patients with a minimum follow-up of 12 months (mean 57.6 ± 8.4 weeks) were included in this analysis. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits.

Results

The mean age of our patients was 59.7 ± 9.3 years. The mean number of IVB injections per eye was three (range: one to six injections) at a mean interval of 14.1 ± 10.5 weeks. In the 1.25 mg group at 1 month BCVA improved from 20/190, logMAR = 0.97 to 20/85, logMAR 0.62, a difference that was statistically significant (p = 0.0001). This improvement was maintained throughout the 3-, 6-, and 12-month follow-up. The mean final BCVA at 12 months was 20/76, logMAR = 0.58 (p < 0.001), a statistically significant difference from baseline BCVA. Similar BCVA changes were observed in the 2.5 mg group. In the 1.25 mg group, the mean central macular thickness (CMT) decreased from 419.1 ± 201.1 µm at baseline to 295.11 ± 91.5 µm at 1 month, 302.1 ± 124.2 µm at 3 months, 313.4.1 ± 96.3 µm at 6 months, and 268.2 ± 95.5 µm at 12 months (p < 0.0001). Similar CMT changes were observed in the 2.5 mg group. Adverse events included transient high blood pressure in one patient (1.2%), transient increased intraocular pressure in one eye (1%), and tractional retinal detachment in one eye (1%).

Conclusions

Primary IVB at doses of 1.25 to 2.5 mg seem to provide stability or improvement in BCVA, OCT, and FA in DDME at 12 months. There seems to be no difference in our results between intravitreal bevacizumab at doses of 1.25 mg or 2.5 mg. In addition, our results suggest the need for at least three injections a year to maintain the BCVA results.

Available only for authorised users

Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787, doi:10.1038/414782a PubMedCrossRef

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464–1474PubMed

Richter B, Kohner E (2004) Medical interventions for diabetic retinopathy. In: Wormald R, Smeeth L, Henshaw K (eds) Evidence-Based Ophthalmology. BMJ Books, London, pp 331–340

Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103:1796–1806

Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: early treatment diabetic retinopathy study report number 2. Ophthalmology 94:761–774

Ferris FL III, Patz A (1984) Macular edema: a complication of diabetic retinopathy. Surv Ophthalmol 28:452–461, doi:10.1016/0039-6257(84)90227-3 PubMedCrossRef

Bresnick GH (1983) Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 90:1301–1317PubMed

Lee CM, Olk RJ (1991) Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 98:1594–60PubMed

Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044–2049, doi:10.1016/j.ophtha.2004.05.025 PubMedCrossRef

10.

Massin P, Aurden F, Houchine B, Erginy A (2004) Intravitreas triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111:218–225, doi:10.1016/j.ophtha.2003.05.037 PubMedCrossRef

11.

Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533–1538, doi:10.1016/j.ophtha.2006.02.065 PubMedCrossRef

12.

Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH (2006) Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 22:200–207, doi:10.1089/jop.2006.22.200 PubMedCrossRef

13.

Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, Gaudric A, Massin P (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 84:624–630, doi:10.1111/j.1600-0420.2006.00700.x PubMedCrossRef

14.

Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD, Macugen Diabetic Retinopathy Study Group (2005) Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747–1757, doi:10.1016/j.ophtha.2005.06.007 PubMedCrossRef

15.

Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM (2006) A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:1706–1712, doi:10.1016/j.ophtha.2006.04.033 PubMedCrossRef

16.

Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005, doi:10.1097/01.iae.0000247165.38655.bf PubMedCrossRef

17.

Starita C, Patel M, Katz B, Adamis AP (2007) Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen®) in diabetic retinopathy. Dev Ophthalmol 39:122–148, doi:10.1159/000098504 PubMedCrossRef

18.

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611, doi:10.1210/er.2003-0027 PubMedCrossRef

19.

Antcliff RJ, Marshall J (1999) The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 14:223–232, doi:10.3109/08820539909069541 PubMedCrossRef

20.

Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110:1690–1696, doi:10.1016/S0161-6420(03)00568-2 PubMedCrossRef

21.

Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed

22.

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487, doi:10.1056/NEJM199412013312203 PubMedCrossRef

23.

Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373–385, doi:10.1016/S0002-9394(01)01381-2 PubMedCrossRef

24.

Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP (1996) Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103:1820–1828PubMed

25.

Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400, doi:10.1038/nrd1381 PubMedCrossRef

26.

Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278, doi:10.1097/00006982-200603000-00004 PubMedCrossRef

27.

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372, doi:10.1016/j.ophtha.2005.11.019 PubMedCrossRef

28.

Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284, doi:10.1097/00006982-200603000-00005 PubMedCrossRef

29.

Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A (2006) (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695,e1–15PubMedCrossRef

30.

Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390, doi:10.1097/00006982-200604000-00001 PubMedCrossRef

31.

Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26:495–511, doi:10.1097/01.iae.0000225766.75009.3a PubMedCrossRef

32.

Oshima Y, Sakaguchi H, Gomi F, Tano Y (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 142:155–158, doi:10.1016/j.ajo.2006.02.015 PubMedCrossRef

33.

Shan PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive retinopathy of prematurity. Indian J Ophthalmol 55:75–76CrossRef

34.

Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME, Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743–750, doi:10.1016/j.ophtha.2006.12.028 PubMedCrossRef

35.

Diabetic Retinopathy Clinical Reseach Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115:1447–1449, doi:10.1016/j.ophtha.2008.06.015 CrossRef

36.

Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329:977–986, doi:10.1056/NEJM199309303291401 CrossRef

37.

UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713

38.

Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M (2005) Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci 46:3855–3858, doi:10.1167/iovs.05-0096 PubMedCrossRef

39.

Campochiaro PA, C99-PKC412-003 Study Group (2004) Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45:922–931, doi:10.1167/iovs.03-0955 PubMedCrossRef

40.

Kumar A, Sinha S (2007) Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Indian J Ophthalmol 55:451–455PubMedCrossRef

41.

Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199–2205, doi:10.1016/j.ophtha.2008.07.007 PubMedCrossRef

42.

Schachat AP, Chambers WA, Liesegang TJ, Albert DA (2003) Safe and effective. Ophthalmology 110:2073–2074, doi:10.1016/S0161-6420(03)01004-2 PubMedCrossRef

Title: Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up
Authors: J. Fernando Arevalo
Juan G. Sanchez
Jans Fromow-Guerra
Lihteh Wu
Maria H. Berrocal
Michel E. Farah
Jose Cardillo
Francisco J. Rodríguez
for the Pan-American Collaborative Retina Study Group (PACORES)
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2009
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-008-1034-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2009

The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy

Weight gain measured at 6 weeks after birth as a predictor for severe retinopathy of prematurity: study with 317 very low birth weight preterm babies

Balloon dacryocystoplasty and monocanalicular intubation with Monoka tubes in the treatment of congenital nasolacrimal duct obstruction

Pupil campimetry in patients with retinitis pigmentosa and functional visual field loss

Role of fructose concentration on cataractogenesis in senile diabetic and non-diabetic patients

Relationship between anterior corneal asphericity and refractive variables